Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells 3,600 Shares of Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $324.73, for a total value of $1,169,028.00. Following the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $42,214.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

United Therapeutics Price Performance

Shares of United Therapeutics stock traded down $1.96 on Monday, hitting $325.72. The company’s stock had a trading volume of 540,024 shares, compared to its average volume of 497,318. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $343.98. The company has a market capitalization of $14.49 billion, a price-to-earnings ratio of 15.20, a price-to-earnings-growth ratio of 1.06 and a beta of 0.55. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.64 and a current ratio of 4.35. The firm has a fifty day moving average price of $308.33 and a 200-day moving average price of $261.54.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The business had revenue of $714.90 million for the quarter, compared to analysts’ expectations of $691.87 million. During the same period in the previous year, the company earned $5.24 EPS. United Therapeutics’s quarterly revenue was up 19.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that United Therapeutics Co. will post 25.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. V Square Quantitative Management LLC acquired a new stake in United Therapeutics in the 2nd quarter valued at about $30,000. Innealta Capital LLC acquired a new stake in shares of United Therapeutics during the 2nd quarter worth about $33,000. Rise Advisors LLC purchased a new stake in United Therapeutics during the first quarter worth approximately $32,000. GAMMA Investing LLC acquired a new position in United Therapeutics in the fourth quarter valued at approximately $43,000. Finally, Benjamin F. Edwards & Company Inc. increased its stake in United Therapeutics by 63.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 117 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

UTHR has been the topic of several research reports. Oppenheimer raised their price objective on United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a report on Thursday, May 2nd. Morgan Stanley downgraded United Therapeutics from an “overweight” rating to an “equal weight” rating and upped their price target for the stock from $310.00 to $321.00 in a research report on Thursday, July 11th. The Goldman Sachs Group increased their price objective on shares of United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. TD Cowen lifted their price objective on shares of United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. Finally, HC Wainwright restated a “buy” rating and issued a $400.00 target price on shares of United Therapeutics in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $331.73.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.